Key result
Lower cardiac radiation dose during SBRT for NSCLC is linked to ~1% lower non-cancer mortality.
Why the study?
The study sought to externally validate a published model describing the association between non-cancer death and cardiac dose in patients with early-stage NSCLC treated with SBRT.
Does a prognostic model incorporating cardiac dose parameters accurately predict non-cancer death and overall survival in early-stage NSCLC patients treated with SBRT?
Observational (n=1,241)
Does a prognostic model incorporating cardiac dose parameters accurately predict non-cancer death and overall survival in early-stage NSCLC patients treated with SBRT?
A prognostic model incorporating cardiac dose successfully predicts non-cancer death and overall survival in early-stage NSCLC patients undergoing SBRT, supporting the clinical utility of cardiac sparing strategies.
Answers are grounded in this paper and cite their sources.
May inform cardiac sparing in SBRT for early NSCLC; extends prior model but remains hypothesis-generating.
BACKGROUND: We use two independent cohorts to externally validate a published model describing the association between non-cancer death (nonCAdeath) and cardiac dose in patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). METHODS: The published model included age, performance status, baseline lung function, baseline cardiac condition, and dose to the left atrium and superior vena cava. The two validation cohorts consisted of 221 and 217 early-stage NSCLC patients. Validation of the Cox-based nonCAdeath model focused on assessing calibration and discrimination. A nomogram was built based on the nonCAdeath model to assess clinical impact at 24 months. In parallel, to account for discrepancies in outcome definition, an overall survival model was built using the original derivation cohort (N = 803) and validated as well. RESULTS: the published nonCAdeath model generalized in one cohort with similar nonCAdeath definition, and the parallel overall survival model validated in both cohorts; the prognostic index was not significantly different between the derivation cohort and validation cohorts, discrimination was comparable across all three cohorts. For the cohorts that validated, the predictions overlapped well with the observed survival, and Hazard ratios for risk groups were comparable between derivation and validation cohorts. The nomogram indicates that for an average patient with a high cardiac dose (22 Gy), a 36% cardiac dose reduction could decrease the risk of nonCAdeath at 24 months by 1%. CONCLUSION: The model that describes the association between cardiac dose parameters, baseline clinical parameters and nonCAdeath after SBRT was externally validated in the cohort with similar outcome definition, while the parallel model with overall survival as endpoint validated in both cohorts. The results from this observational validation study strengthen the robustness of the nonCAdeath model guidance for cardiac sparing.
No takes yet. Share an insight, caveat, or question.
Stam et al. (2026) conducted an observational in Early-stage non-small cell lung cancer (NSCLC) (n=1,241). Cardiac radiation dose vs. Lower cardiac radiation dose was evaluated on Non-cancer death and overall survival. A published model associating cardiac radiation dose with non-cancer death after SBRT in early-stage NSCLC was externally validated, indicating a 36% dose reduction could decrease 24-month risk by 1%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: